Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Anticoagulants in development at DuPont Merck

April 1, 1998

Potent and selective PDE III inhibitor in development at Otsuka

March 31, 1998

New antiplatelet and antithrombotic agent characterized by Taisho

March 31, 1998

Toyama researchers characterize antiplatelet/antithrombotic effects of T-250

March 31, 1998

Platelet antiaggregatory effects of liposome-encapsulated streptokinase

March 30, 1998

Z-335 demonstrates beneficial effects in models of peripheral circulatory insufficiency

March 30, 1998

DuPont Merck obtains U.S. rights for anticoagulant

March 27, 1998

Selective factor Xa inhibitors in development at Banyu

March 25, 1998

Antiplatelet agents disclosed by Nippon Steel

March 25, 1998

PPL reports expression of FIX at high concentrations in milk of transgenic sheep

March 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.